Sana生物科技

US · SANA #3404 按市值排名上市于 2021

2.27 -0.21 -8.28%

实时 - 追踪5344个代码 - 心跳于9秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了1家。
机构持股总比例下降了3.3个百分点。

机构持股

机构持股比例: 79.12% -3.34pp
机构数量: 241 -1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund34.19%

Mutual Fund31.68%

Individual/Insider6.30%

Public Company4.79%

Hedge Fund4.07%

Government Pension Fund3.62%

Private Company0.54%

Insurance Company0.12%

Family Office/Trust0.10%

Other14.59%

主要股东截至 2026-06-30

Arch Venture Partners, L.P. 15.32% · 45.86M 股

FMR 10.99% · 32.89M 股

Flagship Pioneering, Inc 8.35% · 25.00M 股

RA Capital Management, L.P. 6.26% · 18.75M 股

BlackRock 5.57% · 16.68M 股

State Street Global Advisors 3.74% · 11.20M 股

Canada Pension Plan Investment Board 3.41% · 10.22M 股

Vanguard Capital Management, LLC 3.21% · 9.61M 股

Steven Harr 2.99% · 8.96M 股

Hans Edgar Bishop 1.96% · 5.85M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 37次买入 · 10次卖出

姓名	职务	持股比例
Arch Venture Partners, L.P.	--	15.32%
Steven Harr	Chief Executive Officer	2.99%
Hans Edgar Bishop	Independent Chairperson	1.96%
Richard Mulligan	Executive Vice Chairman & Head of Innovation Research	0.90%
Nathan Hardy	Chief Financial Officer	0.15%
Douglas Cole	Independent Director	0.07%
Susan Wyrick	Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting	0.07%
Dhavalkumar Patel	Chief Scientific Officer	0.06%
Yuhmin Yang	Independent Director	0.05%
Bernard Cassidy	General Counsel	0.04%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-26	Dhavalkumar Patel	Chief Scientific Officer	Derivative Exercise and Sale	-41,158	$4.11
2026-08-25	Dhavalkumar Patel	Chief Scientific Officer	Derivative Exercise and Retained	+83,842	--
2026-07-05	Hans Edgar Bishop	Independent Chairperson	Other Acquisition	+6,297	--
2026-06-03	Robert Taylor Nelsen	Independent Director	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Yuhmin Yang	Independent Director	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Michelle Seitz	Independent Director	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Richard Mulligan	Executive Vice Chairman & Head of Innovation Research	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Hans Edgar Bishop	Independent Chairperson	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Joshua Bilenker	Independent Director	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Alise Reicin	Independent Director	Other Derivative Acquisition	+90,000	$2.96
2026-06-03	Robert Rosiello	Director	Other Derivative Acquisition	+90,000	$2.96
2026-04-05	Hans Edgar Bishop	Independent Chairperson	Other Acquisition	+7,763	--
2026-03-23	Dhavalkumar Patel	Chief Scientific Officer	Initial Statement of Beneficial	0	--
2026-03-08	Steven Harr	Chief Executive Officer	Derivative Exercise and Sale	-24,345	$3.10–3.13
2026-03-08	Susan Wyrick	Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting	Derivative Exercise and Sale	-4,387	$3.10–3.13
2026-03-06	Steven Harr	Chief Executive Officer	Derivative Exercise and Retained	+67,321	--
2026-03-05	Susan Wyrick	Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting	Derivative Exercise and Retained	+9,279	--
2026-03-04	Steven Harr	Chief Executive Officer	Other Derivative Acquisition	+200,000	--
2026-03-04	Steven Harr	Chief Executive Officer	Other Derivative Acquisition	+900,000	$3.41
2026-03-04	Susan Wyrick	Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting	Other Derivative Acquisition	+45,833	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。